TABLE 3.
Baseline characteristics of COVID-19 patients before and after propensity score matching.
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| Variables | YDJDG | Lopinavir-Ritonavir | p value | YDJDG | Lopinavir-Ritonavir | p value |
| (n = 60) | (n = 71) | (n = 50) | (n = 50) | |||
| Median age (range) | 41 (6–84) | 41 (18–86) | 0.982 a | 41 (6–84) | 41 (18–82) | 0.730 a |
| Gender (M/F) | 30/30 | 38/33 | 0.688 b | 24/26 | 28/22 | 0.423 c |
| Median days from illness onset to admission time (range) | 5 (1–38) | 5 (0–29) | 0.838 c | 5 (1–38) | 4 (0–15) | 0.530 b |
| Coexisting comorbidity | ||||||
| Hypertension | 11 (18.3) | 12 (16.9) | 0.830 b | 9 (18.0) | 8 (16.0) | 0.790 c |
| Diabetes | 2 (3.3) | 3 (4.2) | 0.791 b | 2 (4.0) | 1 (2.0) | 0.558 c |
| Cardiovascular disease | 4 (6.7) | 2 (2.8) | 0.294 b | 3 (6.0) | 2 (4.0) | 0.646 c |
| Chronic obstructive pulmonary disease | 1 (1.7) | 2 (2.8) | 0.661 b | 1 (2.0) | 1 (2.0) | 1.000 c |
| No. of coexisting comorbidities | ||||||
| None | 45 (75.0) | 57 (80.3) | 0.468 b | 37 (74.0) | 41 (82.0) | 0.334 c |
| One | 12 (20.0) | 10 (14.1) | 0.367 b | 11 (22.0) | 6 (12.0) | 0.183 c |
| Two | 3 (5.0) | 4 (5.6) | 0.872 b | 2 (4.0) | 3 (6.0) | 0.646 c |
| Disease type | ||||||
| Mild | 12 (20.0) | 3 (4.2) | 0.005 b | 4 (8.0) | 3 (6.0) | 0.695 c |
| Moderate | 37 (61.7) | 58 (81.7) | 0.011 b | 37 (74) | 44 (88.0) | 0.074 c |
| Severe | 4 (6.7) | 9 (12.7) | 0.252 b | 4 (8.0) | 2 (4.0) | 0.400 c |
| Critical | 7 (11.7) | 1 (1.4) | 0.015 b | 5 (10.0) | 1 (2.0) | 0.092 c |
| Neutrophil count, × 10⁹/L | 3.1 (2.1–4.1) | 3.2 (2.3–4.1) | 0.773 c | 2.6 (1.0–3.9) | 2.9 (2.3–3.8) | 0.422 b |
| Lymphocyte count, × 10⁹/L | 1.3 (0.9–1.8) | 1.2 (1.0–1.7) | 0.794 c | 1.3 (0.9–1.8) | 1.2 (1.0–1.6) | 0.428 b |
| NLR | 2.4 (1.6–3.3) | 2.6 (1.7–3.9) | 0.759 c | 2.3 (1.5–3.1) | 2.6 (1.8–3.5) | 0.329 b |
| C-reactive protein, mg/L | 8.5 (1.4–18.6) | 11.4 (2.6–28.5) | 0.712 c | 11.1 (1.5–18.6) | 10.6 (2.4–29.0) | 0.869 b |
| CD4, cells/ul | 621.1 ± 206.1 | 680.1 ± 159.9 | 0.067 a | 605.1 ± 218.0 | 628.7 ± 111.6 | 0.498 b |
| Multiple lung lobe or bilateral involvement | 37 (61.7) | 54 (76.1) | 0.075 b | 34 (68.0) | 40 (80.0) | 0.147 c |
Data are presented as median (range), n (%), median (interquartile range), or means ± SD.
a
p values comparing YDJDG group and lopinavir-ritonavir group are from t-test.
b
Mann-Whitney U test.
c
χ2 test.
COVID-19, 2019 coronavirus disease; YDJDG, Yindan Jiedu Granules; NLR, neutrophil-to-lymphocyte ratio.